Oncotelic Therapeutics, Inc.
OTLC
$0.03
$0.001.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 117.69% | -100.88% | 24,001.86% | -476.90% | 193.04% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 7.42% | 132.96% | 14.68% | 29.15% | 8.48% |
| Total Other Non-Cash Items | -145.10% | 100.72% | -49,415.74% | 192.24% | -8,796.77% |
| Change in Net Operating Assets | 264.39% | 59.58% | -255.34% | 68.03% | 6.46% |
| Cash from Operations | 73.06% | 56.30% | -155.05% | -143.26% | 24.43% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -47.98% | -20.72% | -26.29% | 365.19% | -15.63% |
| Total Debt Repaid | 200.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -32.30% | -31.52% | -26.29% | 365.19% | -15.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 585.71% | 92.13% | -199.72% | 3,547.73% | 225.71% |